In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant Pseudomonas Aeruginosa. (8th October 2020)

• Record Type: Journal Article
• Authors: Carr, Donna; Zhang, Zufei; Si, Qian; Racine, Fred; Xiao, Jing Chen; Katwaru, Ravi; Wismer, Michael K; Johnson, Matthew G; Feng, Hwa-Ping; Young, Katherine; Rizk, Matthew L; Motyl, Mary
• Is Part Of: Open forum infectious diseases. Volume 7:Number 11(2020)
• Publication Date: 2020-10-08
• Subjects: antibacterial resistance -- hollow-fiber infection model -- pharmacokinetics/pharmacodynamics -- Pseudomonas aeruginosa; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofaa469
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Our hollow-fiber infection model simulated the projected steady-state pharmacokinetics of ceftolozane and tazobactam in lung epithelial lining fluid of patients with pneumonia receiving 3 g of ceftolozane/tazobactam every 8 hours. Results confirmed the previously established in vitro activity of ceftolozane/tazobactam at and above approved breakpoints against multidrug-resistant Pseudomonas aeruginosa, regardless of Pseudomonas -derived cephalosporinase allele.